COVID-19 Vaccine Tracker Mobile Form - GoCanvas

A critical component to safely reopening businesses during the pandemic includes widespread vaccination. By having workers and employees protected against the novel coronavirus or SARS-CoV-19 virus, companies can ensure their employees' and visitors' safety. Widespread vaccination helps sustain continued business operations, improves employee confidence, and minimizes impacts on the healthcare system by reducing hospitalizations. Currently, vaccine distribution is underway throughout the U.S., with many people receiving their first doses and second doses based on eligibility established by health departments on a state by state basis.

There are multiple COVID-19 vaccines available for the general public. Others are awaiting approval by the Food and Drug Administration (FDA) and distribution through the Centers for Disease Control and Prevention (CDC). The two most widespread vaccines in use include the Pfizer/Pfizer-Biontech and Moderna vaccines, which require two doses. The AstraZeneca, Novavax, and Johnson & Johnson vaccines (as of publishing, still are pending approval) will require only a single dose. Other vaccines are in clinical trials and may be available shortly. This form allows an employee to document their name, the location where they operate from, their team or division, how many vaccine doses they have received, and the date of the final vaccination.

The COVID-19 vaccine tracker is an opportunity for businesses to understand how their employees are protected as a part of the vaccine rollout so that they can implement proper public health measures in the return-to-work process. Those employees who have received the COVID-19 vaccination are likely to have protective antibodies against the virus, which provides them with a protection level that unvaccinated workers may not have. It is essential that businesses still adhere to social distancing measures and other guidelines published by local, state, and federal government agencies, such as the CDC guidelines for returning to work. It is unknown whether either vaccine type (the mRNA vaccine or the Inactivated Virus vaccine) prevents the coronavirus spread.